Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2017-08-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
关于公司及子公司向关联方周战先生续租房产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction where the company and its subsidiary renew a lease agreement with a related party who is also a shareholder and director. It details the transaction terms, pricing policy, approvals by the board and independent directors, and includes opinions from the sponsor institution. The document is a formal disclosure of a related party transaction rather than a financial report, earnings release, or management discussion. It does not contain financial statements or quarterly/yearly results. It is also not a regulatory certification or a report publication announcement. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about a related party transaction that does not fit other specific categories.
2017-08-18 Chinese
2017年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "西藏易明西雅医药科技股份有限公司 2017 年半年度报告全文" which translates to "Tibet Aim Pharmaceutical Technology Co., Ltd. 2017 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, and other comprehensive information for the half-year period ending June 30, 2017. The document includes sections such as company profile, financial indicators, business summary, management discussion and analysis, and financial statements. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly identify it as a comprehensive interim/quarterly financial report covering a period shorter than a full fiscal year, with substantive financial data and analysis. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-18 Chinese
2017年上半年财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "西藏易明西雅医药科技股份有限公司 二〇一七年上半年财务报告 (未经审计)" which translates to "Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. 2017 Half-Year Financial Report (Unaudited)". It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and changes in equity for the period ending June 30, 2017. The length of the document is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial data and analysis for a period shorter than a full fiscal year (half-year). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2017
2017-08-18 Chinese
关于公司使用部分闲置自有资金购买短期理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by a company regarding the use of idle funds to purchase short-term financial products. It details the board's approval, investment purpose, risk control measures, and opinions from independent directors and supervisory board. The document is a formal disclosure about financing activities but does not contain financial statements or detailed financial results. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or a voting result. The content fits best with a Capital/Financing Update as it concerns the company's use of funds and investment in financial products. The document length is about 2500 characters, which is typical for an announcement rather than a full report. Therefore, the classification is Capital/Financing Update (CAP).
2017-08-18 Chinese
独立董事关于公司及子公司向关联方周战先生续租房产的事前认可意见
Regulatory Filings Classification · 95% confidence The document is an independent director's prior approval opinion regarding a related party transaction involving the company's lease renewal of property from a related party. It discusses compliance with listing rules and company articles, fairness of the transaction, and the approval process. There are no financial statements, earnings data, or report publication announcements. The content is focused on governance and compliance related to a specific transaction and board procedures. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement about a related party transaction and independent director opinion, not a full report or financial statement.
2017-08-18 Chinese
独立董事关于第一届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion report from the independent directors of a company regarding various matters discussed at the 19th meeting of the first board of directors. It includes opinions on related party transactions, use of raised funds, purchase of financial products, bank credit applications, and accounting policy changes. The document references regulatory guidelines and compliance but does not contain full financial statements or detailed financial results. It is a formal board-related opinion document rather than a full annual or interim report, audit report, or earnings release. It is not a short announcement or certification but a detailed independent opinion on board matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including independent director opinions on board meetings.
2017-08-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.